Similar to the results from serum ALT levels, NAC treatment significantly diminished serum AST levels in NAFLD-induced animals (SMD: −3.1; 95% CI: −4.0 to −2.2 IU L-1; p-value < 0.01) (Figure 5B). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.